Article author and evidence
Dr. Kainat Amjad, MBBS
Dr. Kainat Amjad writes about practical healthcare operations and patient access.
What Should Dermatology Practices Prioritize?
Capture complete evidence
Record diagnosis, severity, prior therapies, response, contraindications, and required supporting findings during the visit.
Submit electronically
Use ePA when available, but confirm attachments, routing, benefit type, and integration limits.
Assign clear ownership
Give one role responsibility for submission, follow-up, renewal, patient updates, and escalation.
Track every request
Separate internal submission time from payer decision time and flag aging cases daily.
Keep accountable decisions
Clinical, prescribing, coding, compliance, and payer-policy judgments stay with qualified owners.
The 2025 AMA survey shows the burden remains substantial
In the American Medical Association’s nationwide 2025 survey of 1,000 practicing physicians, 95% reported that prior authorization delayed access to necessary care at least sometimes, 79% said it could at least sometimes lead to treatment abandonment, and practices reported an average of 40 requests and 13 hours of physician and staff work per physician each week. These are physician-reported national findings, not dermatology-only measures, but they show why specialty practices need a visible, accountable authorization workflow.
Why Is Prior Authorization a Significant Challenge in Dermatology?
Dermatology combines common chronic conditions with specialty medications, biologics, procedures, phototherapy, and benefit rules that can change by payer and product. The challenge is not a single form. It is the need to match each patient’s treatment and benefit to the current documentation and submission path.
Practices may encounter authorization requirements for biologics used in psoriasis or atopic dermatitis, advanced topical therapies, immunomodulators, phototherapy, Mohs surgery or other procedures, diagnostic services, and specialty-pharmacy medications. Isotretinoin can add a separate operational layer because payer authorization and iPLEDGE requirements are distinct processes.
Medication evidence
Diagnosis, disease severity, prior treatment, response, contraindications, and relevant monitoring information may be required.
Benefit routing
Medical-benefit procedures and pharmacy-benefit medications can follow different systems, policies, reviewers, and timelines.
Renewal cycles
Time-limited approvals, formulary changes, insurance transitions, and therapy continuation can create recurring work after the first decision.
How Do Prior Authorization Delays Affect Dermatology Patients?
Prior authorization can postpone treatment starts, interrupt established therapy, require additional visits or interim management, and contribute to patients abandoning a recommended course of treatment. Dermatology research has associated PA with treatment delays and reduced adherence, while national physician surveys report broader access and abandonment concerns.
The effect depends on the condition, treatment, duration, and available alternatives. A practice should therefore avoid assuming every delay produces the same clinical outcome. Instead, flag cases where symptoms are worsening, therapy is interrupted, or a patient’s ability to continue the process is at risk, and route those cases to the treating clinician.
- Delayed start of prescribed therapy
- Interrupted or missed treatment
- Additional visits or communication while coverage is unresolved
- Patient frustration and treatment abandonment
- Potential worsening that requires clinician assessment
What Operational Challenges Do Dermatology Practices Face?
Each request can require benefit verification, policy review, document gathering, payer-specific forms, record uploads, specialty-pharmacy coordination, status checks, responses to missing-information notices, appeals, renewals, and patient updates. When those tasks are split across staff without a named owner, follow-up becomes difficult to see and easy to defer.
| Workflow stage | Administrative work | Accountable decision |
|---|---|---|
| Intake and benefit check | Confirm plan, benefit, authorization requirement, destination, and current policy | Practice defines which sources and policies staff may rely on |
| Clinical packet | Gather notes, history, scores, labs, pathology, and prior therapy records already documented | Clinician confirms accuracy, medical necessity, and treatment rationale |
| Submission | Complete the form, attach evidence, submit, and record confirmation | Qualified owners review coding or clinical items that require judgment |
| Follow-up | Track status, missing information, due dates, renewal dates, and patient communication | Practice sets urgency and escalation rules |
| Denial or appeal | Obtain the denial reason, assemble records, prepare the administrative appeal packet, and schedule peer-to-peer activity | Clinician, coder, or payer-contract owner decides the substantive response |
What Are the Most Common Causes of Prior Authorization Delays?
Many delays occur at the boundary between changing payer rules and incomplete internal workflow. Missing treatment history, absent severity measures, wrong benefit routing, incomplete attachments, outdated formulary assumptions, manual handoffs, and unclear ownership can all create rework or trigger requests for more information.
External factors
- Payer criteria and formulary changes
- Step-therapy or site-of-care requirements
- Medical versus pharmacy benefit routing
- Payer review and requests for additional information
- Insurance transitions and renewal rules
Internal factors
- Incomplete or inconsistent documentation
- Fax, spreadsheet, inbox, and portal fragmentation
- No named request owner
- Unclear escalation and patient-update rules
- Failure to distinguish submission time from payer decision time
How Can Prior Authorization Delays Affect Practice Revenue?
Authorization problems can contribute to rescheduled procedures, delayed service delivery, staff rework, more patient communication, and longer billing or collection timelines. The financial effect varies by service mix, benefit design, staffing model, and whether the treatment or procedure proceeds.
Practices should measure the effect directly instead of assuming every authorization delay becomes a denial or lost revenue. Link the request to scheduled services, staff touches, patient disposition, and eventual payer determination so leaders can see where time and revenue are actually affected.
What Is Changing for Prior Authorization in 2026 and 2027?
CMS-0057-F requires affected Medicare Advantage organizations and specified Medicaid and CHIP payers to send decisions for non-drug medical items and services within 72 hours for expedited requests and seven calendar days for standard requests. Beginning in 2026, affected payers must also provide a specific denial reason. The decision-timeframe policy excludes qualified health plan issuers on the Federally Facilitated Exchanges, and the rule’s prior authorization provisions do not apply to drug decisions.
CMS-0057-F generally requires affected payers to implement Prior Authorization APIs beginning in 2027. In April 2026, CMS separately proposed standards and timeframes for drug prior authorization. That proposal should not be described as a final drug-PA mandate unless and until CMS finalizes it.
How Can Dermatology Practices Reduce Avoidable Prior Authorization Delays?
Practices cannot control the payer’s final coverage decision, but they can reduce avoidable internal delay by making requirements visible, collecting evidence earlier, assigning ownership, and tracking every exception.
1. Verify the path
Confirm the plan, benefit, authorization requirement, destination, and current payer criteria.
2. Capture evidence
Use visit prompts for severity, prior therapy, response, contraindications, labs, pathology, and rationale.
3. Submit electronically
Use ePA or a supported portal when available and retain confirmation and attachment records.
4. Name the owner
Assign responsibility for status, next action, patient updates, renewals, and escalation.
5. Review exceptions
Check aging requests, missing information, denials, expiring approvals, and urgent clinical flags daily.
6. Learn monthly
Review causes by payer, medication, procedure, location, and workflow stage, then update templates.
Use electronic prior authorization where it fits
Electronic submission can reduce reliance on fax and phone communication and improve status visibility. It is not a universal solution: payer connectivity, EHR integration, attachments, pharmacy routing, and clinical review still vary.
Standardize documentation without standardizing clinical judgment
Build treatment- and payer-specific prompts for common medications and procedures. Templates should help clinicians record the relevant facts, not dictate a diagnosis, score, treatment choice, or medical-necessity conclusion.
Maintain a centralized tracker
At minimum, track patient and request identifiers, payer, benefit type, treatment or procedure, submission date, confirmation, current status, next action, owner, missing information, decision date, denial reason, appeal status, renewal date, and patient communication.
What Are Dermatology Providers Asking About Authorization Workflows?
Provider conversations focus on authorization requirements spreading beyond biologics, documentation demands for specialty medications, EHR integration limits, formulary changes, renewals, and the need for dedicated coordinators. The discussion shapes the questions; authoritative and operational sources shape the answers.
Is prior authorization expanding beyond biologics to common dermatology medications?
Providers describe authorization requests appearing for topical retinoids, topical dapsone, immunomodulators, corticosteroids, and other medications that previously felt routine. Requirements still vary by plan, indication, age, formulary, and benefit manager, so the safest response is to verify the current patient-specific rule instead of relying on last year's experience. A governed administrative team can maintain payer references and route exceptions, while the dermatologist retains prescribing and clinical-alternative decisions.
What should dermatologists document during the visit for a biologic request?
Capture the diagnosis, severity measures used by the practice, affected body area, prior therapies with dose, duration, response, and reason stopped, relevant contraindications, and current supporting findings required by the patient's payer policy. The exact packet is treatment- and plan-specific. Administrative support can maintain templates and assemble available records, but the treating clinician must confirm medical necessity, accuracy, and the clinical rationale before submission.
Can electronic prior authorization solve the entire dermatology backlog?
No. Electronic prior authorization can improve transmission, status visibility, and structured data exchange, but it does not remove changing formularies, step-therapy rules, missing clinical evidence, or payer review. Integration depth also varies across EHRs, pharmacy systems, and payers. A dedicated administrative owner can manage queues, attachments, follow-up, and exception tracking, while clinicians and practice leaders keep responsibility for clinical decisions, vendor selection, and escalation policy.
Who should own renewals, denials, and specialty-pharmacy follow-up?
Assign one accountable role or team to each request from intake through determination, renewal, or appeal. The owner should maintain the status, next action, due date, missing information, payer contact, patient update, and escalation path. Outsourced administrative support may perform this coordination under the practice's approved workflow, but peer-to-peer clinical discussions, prescribing choices, coding judgment, and final appeal positions remain with qualified internal owners.
Should Dermatology Practices Consider Outsourcing Prior Authorization?
Outsourcing may fit a practice that has sustained authorization volume, limited internal capacity, inconsistent follow-up, or no practical way to dedicate a full-week coordinator. The goal is to assign defined administrative work to a named team under the practice’s access, documentation, quality, and escalation rules.
Administrative work that may be delegated
- Benefit and authorization requirement checks
- Document gathering and packet assembly
- Submission and confirmation capture
- Status tracking, renewal tracking, and patient updates
- Denial intake and appeal preparation
- Payer and specialty-pharmacy coordination
Responsibility the practice retains
- Diagnosis, prescribing, and medical necessity
- Clinical severity measures and treatment rationale
- Coding and payer-contract interpretation requiring judgment
- Peer-to-peer clinical discussion
- Privacy, security, compliance, and vendor governance
- Final appeal and escalation decisions
When comparing partners, ask how they distinguish time to submission from payer decision time, how missing information is escalated, who owns renewals, how access is limited and removed, how status is visible inside the practice’s workflow, and which tasks always return to a clinician or qualified internal owner.
Which Prior Authorization KPIs Should Dermatology Practices Monitor?
Measure each stage separately. A single average can hide whether the delay occurred before submission, during payer review, after a request for more information, or during an appeal.
| Metric | Definition | Why it helps |
|---|---|---|
| Order-to-submission time | Elapsed time from the complete internal request to confirmed submission | Shows the delay the practice or support team can influence directly |
| Submission-to-decision time | Elapsed time from confirmed submission to payer determination | Separates payer review from internal processing |
| Pending-case age | Days each open request has remained unresolved | Surfaces stalled cases and urgent exceptions |
| First-pass determination | Approval, denial, or request for more information after the initial submission | Shows packet completeness and policy alignment without treating approval as guaranteed |
| Denial reason and appeal outcome | Categorized denial reason, appeal action, and final determination | Identifies recurring documentation, coverage, coding, or policy issues |
| Staff touches and time | Number of handoffs, calls, messages, and estimated labor minutes per request | Shows administrative burden and fragmentation |
| Patient disposition | Treatment started, alternative selected, delayed, or abandoned after authorization activity | Connects operational work to access while preserving clinical nuance |
How Can Staffingly Support Dermatology Prior Authorization Workflows?
Staffingly provides dedicated healthcare administrative support for benefit verification, prior authorization coordination, document management, status tracking, denial follow-up, appeal preparation, and payer or specialty-pharmacy communication. AAPC-certified specialists may support assigned roles where certification applies. The practice keeps clinical, prescribing, coding, privacy, compliance, payer-policy, and final escalation responsibility.
Staffingly’s approved operating standard is: “We aim to prepare and submit complete prior-authorization requests within four business hours of receiving all required information during normal business hours.” This is a submission target, not a promise of payer approval. Typical authorization processing is approximately 24 to 48 hours, depending on payer response, clinical complexity, and documentation.
Typical onboarding and go-live take approximately one to two weeks, and a Two-Week Free Trial is available. Staffingly’s HIPAA-compliant AI Clinical Sandbox may assist with PA validation before submission, but it supports rather than replaces licensed clinical judgment, qualified review, or client approval. The service should be measured against the practice’s own baseline, payer mix, case complexity, and agreed workflow.
Review Staffingly’s dermatology prior authorization workflow or explore the prior authorization service hub.
Frequently Asked Questions
Why do dermatology treatments require prior authorization?
Health plans and benefit managers use prior authorization to check whether a medication, procedure, imaging study, or other service meets the plan's coverage and medical-necessity criteria before payment. Requirements vary by plan and benefit.
Which dermatology treatments commonly require prior authorization?
Depending on the plan, prior authorization may apply to biologics, advanced topical therapies, immunomodulators, phototherapy, Mohs surgery or other procedures, diagnostic services, and specialty-pharmacy medications. Isotretinoin may also involve both payer authorization and separate iPLEDGE requirements.
Does the CMS prior authorization rule speed up dermatology drug approvals?
Not under CMS-0057-F. Its decision timeframes and related requirements apply to affected non-drug medical items and services, not drug prior authorizations. CMS proposed separate drug prior authorization standards in 2026, but a proposal is not a final requirement.
How can practices reduce authorization delays?
Use payer-specific documentation prompts, electronic submission when available, a dedicated owner, a centralized tracker, daily exception review, patient communication, and a routine process for checking formulary and policy changes.
What can happen when prior authorizations are delayed?
Patients may experience postponed treatment, interrupted therapy, additional visits, frustration, or treatment abandonment. Practices may face more administrative work, rescheduling, delayed service delivery, and longer billing or collection timelines.
Can a dermatology practice outsource prior authorization work?
Yes. A practice may delegate administrative work such as benefit verification, document gathering, submission, status tracking, patient updates, and appeal preparation under an approved workflow. The practice retains clinical, prescribing, coding, privacy, compliance, payer-policy, and final escalation responsibility.
What Are the Short Answers to Common Dermatology PA Questions?
These concise answers separate controllable administrative work from payer decisions and clinical responsibility.
What causes dermatology prior authorization delays?
Delays commonly arise from payer-specific criteria, changing formularies, incomplete treatment history, missing severity measures, unclear ownership, manual submission, and slow follow-up on requests for more information.
How can dermatology practices reduce prior authorization delays?
Capture required evidence during the visit, verify the current payer rule, submit electronically when available, assign a named owner, track every request and renewal, and use a defined escalation path for missing information or denials.
Does CMS-0057-F cover dermatology drug prior authorization?
No. CMS-0057-F's prior authorization requirements apply to affected non-drug medical items and services. They do not apply to prior authorization decisions for drugs, so prescription biologics and other pharmacy-benefit requests follow separate rules.
What should practices measure in a dermatology authorization workflow?
Track time from order to submission, time from submission to payer decision, first-pass determinations, denial reasons, appeal outcomes, pending-case age, staff touches, renewal timeliness, and treatment starts delayed or abandoned after authorization problems.
What Is the Practical Next Step for a Dermatology Practice?
Prior authorization is unlikely to disappear from dermatology, but practices do not have to accept invisible queues and preventable rework. Start with one high-volume medication or procedure, map every step, capture required evidence during the visit, assign one owner, and review exceptions daily.
Then measure order-to-submission time, payer decision time, missing-information requests, denial reasons, staff touches, renewals, and patient disposition. That creates a defensible baseline for deciding whether templates, electronic tools, staffing changes, or governed outside support will help.
Sources Referenced
Search Sources Reviewed
Google surfaced the following industry and vendor pages. They were reviewed for search intent and terminology, not used as primary evidence for healthcare or performance claims.
Ready to Make Every Authorization Request Visible and Accountable?
Map one high-volume workflow, define the required evidence, assign ownership, separate submission time from payer decision time, and set the clinical escalation path before adding capacity.